title: Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase.
abstract: Succinate semialdehyde dehydrogenase (ALDH5A1, encoding SSADH deficiency is a defect of 4-aminobutyric acid (GABA) degradation that manifests in humans as 4-hydroxybutyric (gamma-hydroxybutyric, GHB) aciduria. It is characterized by a non-specific neurological disorder including psychomotor retardation, language delay, seizures, hypotonia and ataxia. The current therapy, vigabatrin (VGB), is not uniformly successful. Here we report the development of Aldh5a1-deficient mice. At postnatal day 16-22 Aldh5a1-/- mice display ataxia and develop generalized seizures leading to rapid death. We observed increased amounts of GHB and total GABA in urine, brain and liver homogenates and detected significant gliosis in the hippocampus of Aldh5a1-/- mice. We found therapeutic intervention with phenobarbital or phenytoin ineffective, whereas intervention with vigabatrin or the GABAB receptor antagonist CGP 35348 (ref. 2) prevented tonic-clonic convulsions and significantly enhanced survival of the mutant mice. Because neurologic deterioration coincided with weaning, we hypothesized the presence of a protective compound in breast milk. Indeed, treatment of mutant mice with the amino acid taurine rescued Aldh5a1-/- mice. These findings provide insight into pathomechanisms and may have therapeutic relevance for the human SSADH deficiency disease and GHB overdose and toxicity.
authors.affiliation: Department of Molecular and Medical Genetics, Oregon Health Sciences University, 2525 SW Third Avenue, Portland, Oregon 97201, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Hogema
authors.forename: M
authors.initials: M
authors.lastname: Gupta
authors.forename: H
authors.initials: H
authors.lastname: Senephansiri
authors.forename: T G
authors.initials: TG
authors.lastname: Burlingame
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.forename: C
authors.initials: C
authors.lastname: Jakobs
authors.forename: R B
authors.initials: RB
authors.lastname: Schutgens
authors.forename: W
authors.initials: W
authors.lastname: Froestl
authors.forename: O C
authors.initials: OC
authors.lastname: Snead
authors.forename: R
authors.initials: R
authors.lastname: Diaz-Arrastia
authors.forename: T
authors.initials: T
authors.lastname: Bottiglieri
authors.forename: M
authors.initials: M
authors.lastname: Grompe
authors.forename: K M
authors.initials: KM
authors.lastname: Gibson
mesh_terms: D000445:Aldehyde Oxidoreductases / Q000235:genetics*; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001483:Base Sequence; D001921:Brain / Q000378:metabolism; D017931:DNA Primers; D005838:Genotype; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006885:Hydroxybutyrates / Q000378:metabolism; D007150:Immunohistochemistry; D051379:Mice; D018345:Mice, Knockout; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D018080:Receptors, GABA-B / Q000378:metabolism; D012640:Seizures / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D050644:Succinate-Semialdehyde Dehydrogenase
chemical_list: D000927:Anticonvulsants; D017931:DNA Primers; D005904:Glial Fibrillary Acidic Protein; D006885:Hydroxybutyrates; D018080:Receptors, GABA-B; C111420:4-hydroxybutyric acid; D010672:Phenytoin; D000445:Aldehyde Oxidoreductases; D050644:Succinate-Semialdehyde Dehydrogenase; D010634:Phenobarbital